Estrogen plus progestin and colorectal cancer incidence and mortality

Journal of Clinical Oncology

Volumn 30, Issue 32, 2012, Pages 3983-3990

  Simon, Michael S ^a   Chlebowski, Rowan T ^b   Wactawski Wende, Jean ^d   Johnson, Karen C ^e   Muskovitz, Andrew ^a   Kato, Ikuko ^a   Young, Alicia ^f   Hubbell, F A ^c   Prentice, Ross L ^f  

^a WAYNE STATE UNIVERSITY   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DRUG TREATMENT FAILURE; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE METASTASIS; VAGINA BLEEDING;

ADULT; AGED; COLORECTAL NEOPLASMS; DELAYED DIAGNOSIS; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PROGESTINS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SAMPLE SIZE; UNITED STATES; WOMEN'S HEALTH;

EID: 84869469022     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.7732     Document Type: Article

References (43)

1. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
2. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al: Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350:991-1004, 2004
3. Lin KJ, Cheung WY, Lai JY, et al: The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 130:419-430, 2012
4. Hawk ET, Levin B: Colorectal cancer prevention. J Clin Oncol 23:378-391, 2005
5. Solimando R, Bazzoli F, Ricciardiello L: Chemoprevention of colorectal cancer: A role for ursodeoxycholic acid, folate and hormone replacement treatment? Best Pract Res Clin Gastroenterol 25:555-568, 2011
6. North American Menopause Society: Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17:242-255, 2010
7. Practice Committee of American Society for Reproductive Medicine: Estrogen and progestogen therapy in postmenopausal women. Fertil Steril 90:S88-S102, 2008
8. Pines A: Guidelines and recommendations on hormone therapy in the menopause. J Midlife Health 1:41-42, 2010
9. Bowring CE, Francis RM: National Osteoporosis Society's Position statement on hormone replacement therapy in the prevention and treatment of osteoporosis. Menopause Int 17:63-65, 2011
10. Sturdee DW, Pines A, Archer DF, et al: Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 14:302-320, 2011
11. Santen RJ, Allred DC, Ardoin SP, et al: Postmenopausal hormone therapy: An Endocrine Society scientific statement. J Clin Endocrinol Metab 95:s1-s66, 2010 (suppl 1)
12. Prentice RL, Pettinger M, Beresford SA, et al: Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev 18:1531-1537, 2009
13. Heiss G, Wallace R, Anderson GL, et al: Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299:1036-1045, 2008
14. Anderson GL, Manson J, Wallace R, et al: Implementation of the Women's Health Initiative study design. Ann Epidemiol 13:S5-S17, 2003 (suppl 9)
15. Hulley S, Grady D, Bush T, et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280:605-613, 1998
16. Curb JD, McTiernan A, Heckbert SR, et al: Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 13:S122-S128, 2003 (suppl 9)
17. National Cancer Institute: Surveillance, Epidemiology, and End Results: About SEER. 2011. http://www.seer.cancer.gov/
18. Chlebowski RT, Anderson GL, Gass M, et al: Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684-1692, 2010
19. Risch HA, Howe GR: Menopausal hormone use and colorectal cancer in Saskatchewan: A record linkage cohort study. Cancer Epidemiol Biomarkers Prev 4:21-28, 1995
20. Persson I, Yuen J, Bergkvist L, et al: Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: Long-term follow-up of a Swedish cohort. Int J Cancer 67:327-332, 1996
21. Pukkala E, Tulenheimo-Silfvast A, Leminen A: Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997. Cancer Causes Control 12:111-115, 2001
22. Tannen RL, Weiner MG, Xie D, et al: Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod 22:1769-1777, 2007
23. Green J, Czanner G, Reeves G, et al: Menopausal hormone therapy and risk of gastrointestinal cancer: Nested case-control study within a prospective cohort, and meta-analysis. Int J Cancer 130: 2387-2396, 2012
24. Johnson JR, Lacey JV Jr, Lazovich D, et al: Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 18:196-203, 2009
25. Hildebrand JS, Jacobs EJ, Campbell PT, et al: Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol Biomarkers Prev 18:2835-2841, 2009
26. Delellis Henderson K, Duan L, Sullivan-Halley J, et al: Menopausal hormone therapy use and risk of invasive colon cancer: The California Teachers Study. Am J Epidemiol 171:415-425, 2010
27. Tsilidis KK, Allen NE, Key TJ, et al: Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 128:1881-1889, 2011
28. American Cancer Society: Cancer Facts and Figures 2010. Atlanta, GA, American Cancer Society, 2010
29. Majumdar SR, Fletcher RH, Evans AT: How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gastroenterol 94:3039-3045, 1999
30. Langenbach MR, Schmidt J, Neumann J, et al: Delay in treatment of colorectal cancer: Multifactorial problem. World J Surg 27:304-308, 2003
31. Siminoff LA, Rogers HL, Thomson MD, et al: Doctor, what's wrong with me? Factors that delay the diagnosis of colorectal cancer. Patient Educ Couns 84:352-358, 2011
32. Grodstein F, Newcomb PA, Stampfer MJ: Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis. Am J Med 106:574-582, 1999
33. Slattery ML, Anderson K, Samowitz W, et al: Hormone replacement therapy and improved survival among postmenopausal women diagnosed with colon cancer (USA). Cancer Causes Control 10:467-473, 1999
34. Mandelson MT, Miglioretti D, Newcomb PA, et al: Hormone replacement therapy in relation to survival in women diagnosed with colon cancer. Cancer Causes Control 14:979-984, 2003
35. Chan JA, Meyerhardt JA, Chan AT, et al: Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol 24:5680-5686, 2006
36. Newcomb PA, Chia VM, Hampton JM, et al: Hormone therapy in relation to survival from large bowel cancer. Cancer Causes Control 20:409-416, 2009
37. Ritenbaugh C, Stanford JL, Wu L, et al: Conjugated equine estrogens and colorectal cancer incidence and survival: The Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 17:2609-2618, 2008
38. Hulley S, Furberg C, Barrett-Connor E, et al: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 288:58-66, 2002
39. Giovannucci E: An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 10:725-731, 2001
40. Krishnan S, Wolf JL: Colorectal cancer screening and prevention in women. Womens Health (Lond Engl) 7:213-226, 2011
41. Paskett ED, Reeves KW, Rohan TE, et al: Association between cigarette smoking and colorectal cancer in the Women's Health Initiative. J Natl Cancer Inst 99:1729-1735, 2007
42. Chlebowski RT: Menopausal hormone therapy, hormone receptor status, and lung cancer in women. Semin Oncol 36:566-571, 2009
43. National Cancer Institute: Colorectal cancer treatment (PDQ). http://www.cancer.gov/cancertopics/pdq/treatment/colon